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Responding to Environmental Issues:
Lessons Learned
Committing resources to one project often means another issue
will go unattended. The potential impact on human health and
environmental quality can be significant. Admittedly, research
career goals provide a subtle but distinctive driving force in priority
setting and allocation of resources. Careers are affected by the
nature of the scientific issues addressed: association with a highly
visible problem is often more career enhancing than association
with a less noteworthy issue. Thus, the response of the scientific
community to emerging issues has a tremendous influence on the
allocation of resources and the availability and capability of our
workforce for future issues.
We, as a scientific community, should responsibly address new
scientific issues by zeroing in on the highest priority needs with
strategies that are in proportion to the size of the problems. Some
examples may be illustrative.
Our response to the endocrine-disruptor (ED) issue is a case in
point. Signals ofadverse effects on wildlife species began to appear
in the published literature in the 1970s (1-7). Effects in humans
claimed to be associated with EDs in the environment were report-
ed more recently (8-16). Attention to EDs hit the national radar
screen with the passage of two laws: the Food Quality Protection
Act in 1996 and the 1996 amendments to the Safe Drinking Water
Act. Enormous amounts of human and laboratory resources were
plowed into developing agreement on test batteries to detect hor-
monal activities of chemicals through the U.S. Environmental
Protection Agency Endocrine Disruptor Screening and Testing
Advisory Committee. Determining whether there were, in fact,
adverse effects in humans from exposure to EDs in the environment
and, if so, characterizing the scope ofthe problem, seemed a much
lower priority. While there is general agreement that EDs cause cer-
tain adverse effects in wildlife species (8), there is no such consensus
about adverse effects in humans. As the issue gained momentum,
many scientists who were active in ED-related research segregated
into camps that focused on discrediting the results of other
researchers (17). Time and resources could have been better spent
building a database for use in evaluating the conditions under which
chemicals with weak hormonal activity might cause adverse effects
in wildlife, domestic animals, and humans. After several years and
many millions of dollars spent on research, conferences, and meet-
ings, we still do not have validated test methods for detection of
endocrine-disruptor activity. We do not know if there is a causal
relationship between adverse health effects in humans and exposure
to EDs in our environment. It seems obvious that our focus should
be on determining whether such a relationship exists and, if so,
characterizing the extent of the problem. Right now, we do not
have the definitive information needed to do that.
Could we have better framed the issue and avoided the pas-
sage of laws that drove a process perhaps magnitudes larger than
the problem warranted? Could we have developed a research
strategy that was more constructive and less defensive? As we con-
tinue to debate whether endocrine-disrupting chemicals are a real
threat to human health, the public
is presented with confusion rather
than resolution. Situations like this
erode the public's confidence in
our interest and ability to solve
problems that, in their minds,
came from the science community
in the first place.
The ED issue is but one example
B.A. Schwetz of a scientific strategy with mixed
agendas. There are other science-
based issues from the recent past that appear to be driven by debat-
able agendas or mandates, for example, the controversy over the
use of recombinant bovine somatotropin, the continued emphasis
on TCDD many years after the sources and risks ofexposure were
understood, the minimal response to the threat of "mad cow dis-
ease," and the failure to use mechanistic data to regulate environ-
mental chemicals such as chloroform. Our responses to these issues
have raised questions in the minds ofsome ofour colleagues about
priorities ofscience, communication with the public, and the rela-
tionship between research results and regulatory decisions.
There is increasing effort today among the federal laboratories
to coordinate research directions and encourage collaboration
rather than competition. Congressional appropriations targeted for
specific research areas encourage more cooperation between federal
agencies but restrict freedom to anticipate new problems. We need
to fight the fires of the day, but still be proactive in identifying
those issues that truly warrant the level of attention we have given
to EDs. Rather than waiting for a public outcry to drive legislative
activity, experts from federal laboratories could provide back-
ground information and perspective to members ofCongress about
the need (or lack thereof) for legislation related to new environ-
mental and human health issues. Antimicrobial resistance is a prob-
lem that requires such a strategy now. A recent General Accounting
Office report summarizes the background and current status ofthis
issue (18). There is no shortage ofcontroversy about antimicrobial
resistance, and opinions about the size of the problem range from
no concern" to "major medical disaster."
As we devise strategies to resolve problems that are in the early
stages ofevaluation, such as the impact ofantimicrobial resistance,
we should heed the lessons learned from our response to the
endocrine-disruptor issue and maintain a balanced approach that
will maximize our efficiency and effectiveness in the future.
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Toxicology: Judge Data or Dollars?
The knowledge gained by our work as toxicologic scientists ranges
from molecular mechanisms to clinical signs oftoxicity, from physi-
ologically based pharmacokinetics to tumor counts. Any of this
research, from any source, may be translated into regulatory action
in order to protect the public and the environment; thus, society is
best served by the best science from every source. The challenge is to
find the criteria to accurately and, increasingly, quickly judge which
studies are valid and appropriate to affect regulation. Cynics make
these quick judgments based on funding sources; traditionalists trust
the proven, but slow, peer-review process; regulatory agencies want
to see raw data from industry, but have implicitly trusted and
exempted academia from this scrutiny. Needs for confidentiality
place limits on disclosure, but they do not preclude a more even and
open approach to data from all sources. Greater disclosure will
result in a scientific process that is faster, better, and more trustwor-
thy-"trust" is the key word here. But, as a former U.S. president
said near the end ofthe Cold War, "Trust but verify."
Verification was the apparent goal ofa few lines buried deep in
the voluminous 1999 Omnibus Spending Bill (1). It states
That the Director of OMB amends section -.36 of OMB Circular A-1 0 to
require Federal awarding agencies to ensure that all data produced under an
award will be made available to the public through the procedures established
under the Freedom ofInformation Act.
This new law has provoked, according to one editorial, "...howls
of protest from scientists, their institutions, and the federal agen-
cies that fund scientific research" (2). However, major scientific
societies, including the American Chemical Society, the Council
for Chemical Research, and the American Association for the
Advancement of Science, all support, in principle, the need to
assess the validity ofsuch research results (3). Recently, it has again
been made clear that the issues ofquality and reliability oftoxicolo-
gy data and its reasoned interpretation for regulatory purposes are
critical (4); the question is how best to accomplish that end.
Researchsh3oiukldbejudgedoni the basisoJfstc.ientific
merit, without regardlforfundlinigsource or- wlhere the
studies are conducted..,
[Society ofToxicology. SOT Principles for Research Priorities in Toxicology.
Available: http://www.toxicology.org/AboutSOT/about.html (1999).]
The tried and true
way, the unfettered
peer-review process,
is and will continue
to be the keystone
of scientific pro-
F gress. However, it
rarely depends on
the scrutiny of raw
data; rather, the
peer-review process
_ 1 _ ultimately depends
Ron R.Miller,JamesS. Bus,andJamesW.Crissman on the independent
replication of
important findings. Thus, it is slow, sometimes painfully so.
Democracy is a similarly empirical endeavor. Like science, the
process is generally ponderous and tentative, and our laws are often
badly out of synchronization with science, a condition regularly
exacerbated by swells of public concern. Fueled by a willing press,
the public perception of a crisis can rapidly propel new regulations
that may never gain a scientific foundation, nor are they repealed
when science catches up. Rational or not, an alarmed public, or
more often issue advocacy groups, call for immediate action well
before any reasoned assessment ofwhat action, if any, is called for.
The scientific community is left unprepared. Poor decisions follow,
which may have unintended consequences, levy unnecessary
expense on taxpayers, and provide no demonstrable benefit for pub-
lic health or the environment.
Unfortunately, as a preventative for bad regulation based on
unvalidated or preliminary science, the new amendment to Circular
A-1 0 is a crude vaccine that will cause more problems than it
could possibly cure. The apparent intent of the law is laudable, but
its shortcomings are serious: It lacks adequate protection for intel-
lectual property, patient privacy, and against legal abuse by those
who might be tempted to harass researchers with unreasonable
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